Long non-coding RNA SNHG16 as a potential biomarker in hepatocellular carcinoma: A meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
10 Sep 2021
10 Sep 2021
Historique:
received:
06
11
2020
accepted:
20
08
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
Small nucleolar RNA host gene 16 (SNHG16) has recently been reported as a potential biomarker in various cancers. However, the prognostic value of SNHG16 in hepatocellular carcinoma (HCC) has not been investigated yet. Therefore, the purpose of this study was to reveal the association between SNHG16 expression and clinicopathological characteristics of HCC.Standards-compliant literature was retrieved from multiple public databases, and data on overall survival, disease-free survival, and clinicopathological characteristics related to SNGH16 were extracted and meta-analysis was performed. Additionally, the Cancer Genome Atlas data were analyzed through the gene expression profiling interactive analysis database to verify previous results.A total of 5 reports involving 410 patients with HCC were enrolled. The high expression of SNHG16 indicated worse overall survival (hazard ratio, 2.10; 95% CI, 1.22-3.60; P = .007) and disease-free survival (hazard ratio, 3.38; 95% CI, 1.10-10.40; P = .03). Additionally, the high expression of SNHG16 predicted a larger tumor size, metastasis, and advanced TNM stage.SNHG16 could serve as a potential biomarker of poor prognosis in HCC.
Identifiants
pubmed: 34516515
doi: 10.1097/MD.0000000000027178
pii: 00005792-202109100-00030
pmc: PMC8428724
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Long Noncoding
0
SNHG16 lncRNA, human
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27178Subventions
Organisme : National Natural Science Foundation of China
ID : 81201549
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Akinyemiju T, Abera S, Ahmed M, et al. Global Burden of Disease Liver Cancer C. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683–91.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:07–34.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301–14.
Makarova-Rusher OV, Altekruse SF, McNeel TS, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016;122:1757–65.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:07–30.
Abdel Ghafar MT, Morad MA, El-Zamarany EA, et al. Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: a pilot study. Int Immunopharmacol 2020;82:106375.
Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015;47:199–208.
Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009;23:1494–504.
Li T, Mo X, Fu L, Xiao B, Guo J. Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget 2016;7:8601–12.
Park SM, Choi EY, Bae DH, Sohn HA, Kim SY, Kim YJ. The lncRNA EPEL promotes lung cancer cell proliferation through E2F target activation. Cell Physiol Biochem 2018;45:1270–83.
Xin B, Liu Y, Li G, Xu Y, Cui W. The role of lncRNA SNHG16 in myocardial cell injury induced by acute myocardial infarction and the underlying functional regulation mechanism. Panminerva Med 2019.
Zheng D, Chen D, Lin F, et al. LncRNA NNT-AS1 promote glioma cell proliferation and metastases through miR-494-3p/PRMT1 axis. Cell Cycle 2020;19:1621–31.
He X, Ma J, Zhang M, Cui J, Yang H. Long non-coding RNA SNHG16 activates USP22 expression to promote colorectal cancer progression by sponging miR-132-3p. Onco Targets Ther 2020;13:4283–94.
Wu W, Guo L, Liang Z, Liu Y, Yao Z. Lnc-SNHG16/miR-128 axis modulates malignant phenotype through WNT/beta-catenin pathway in cervical cancer cells. J Cancer 2020;11:2201–12.
Xu P, Xiao H, Yang Q, et al. The USP21/YY1/SNHG16 axis contributes to tumor proliferation, migration, and invasion of non-small-cell lung cancer. Exp Mol Med 2020;52:41–55.
Guo Z, Zhang J, Fan L, et al. Long noncoding RNA (lncRNA) small nucleolar RNA host gene 16 (SNHG16) predicts poor prognosis and sorafenib resistance in hepatocellular carcinoma. Med Sci Monit 2019;25:2079–86.
Zhong JH, Xiang X, Wang YY, et al. The lncRNA SNHG16 affects prognosis in hepatocellular carcinoma by regulating p62 expression. J Cell Physiol 2020;235:1090–102.
Wang L, Qi Y, Wang Y, et al. LncRNA MALAT1 suppression protects endothelium against oxLDL-induced inflammation via inhibiting expression of MiR-181b target gene TOX. Oxid Med Cell Longev 2019;2019:8245810.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Response to: Practical methods for incorporating summary time-to-event data into meta. Authors’ reply. Trials 2013;14:391.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017;45:W98–102.
Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57–74.
Hu G, Niu F, Humburg BA, et al. Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis. Oncotarget 2018;9:18648–63.
Ahmadi S, Zobeiri M, Bradburn S. Molecular mechanisms underlying actions of certain long noncoding RNAs in Alzheimer's disease. Metab Brain Dis 2020;35:681–93.
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011;43:904–14.
Kansara S, Pandey V, Lobie PE, Sethi G, Garg M, Pandey AK. Mechanistic involvement of long non-coding RNAs in oncotherapeutics resistance in triple-negative breast cancer. Cells 2020;9:
Neve B, Jonckheere N, Vincent A, Van Seuningen I. Epigenetic regulation by lncRNAs: an overview focused on UCA1 in colorectal cancer. Cancers (Basel) 2018;10:
Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer 2020;19:77.
Piao M, Zhang L. Knockdown of SNHG16 suppresses the proliferation and induces the apoptosis of leukemia cells via miR193a5p/CDK8. Int J Mol Med 2020;46:1175–85.
Wang X, Liu L, Zhao W, Li Q, Wang G, Li H. LncRNA SNHG16 promotes the progression of laryngeal squamous cell carcinoma by mediating miR-877-5p/FOXP4 axis. Onco Targets Ther 2020;13:4569–79.
Shao M, Yu Z, Zou J. LncRNA-SNHG16 silencing inhibits prostate carcinoma cell growth, downregulate GLUT1 expression and reduce glucose uptake. Cancer Manag Res 2020;12:1751–7.
Chen H, Li M, Huang P. LncRNA snhg16 promotes hepatocellular carcinoma proliferation, migration and invasion by regulating miR-186 expression. J Cancer 2019;10:3571–81.
Xu F, Zha G, Wu Y, Cai W, Ao J. Overexpressing lncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-miR-93. Onco Targets Ther 2018;11:8855–63.
West CA, Black AP, Mehta AS. Analysis of hepatocellular carcinoma tissue for biomarker discovery. In: Hepatocellular Carcinoma: Translational Precision Medicine Approaches. edn. Edited by Hoshida Y. Cham (CH); 2019: 93–107.
Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol 2017;1018:11–21.
Abdel Ghafar MT, Gharib F, Abdel-Salam S, et al. Role of serum Metadherin mRNA expression in the diagnosis and prediction of survival in patients with colorectal cancer. Mol Biol Rep 2020;47:2509–19.
Abdel Ghafar MT, Elkhouly RA, Elnaggar MH, et al. Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma. J Investig Med 2021.
Habib EM, Nosiar NA, Eid MA, et al. Circulating miR-146a expression predicts early treatment response to imatinib in adult chronic myeloid leukemia. J Investig Med 2021;69:333–7.